TriangleDISEASE & TREATMENT SETTING
Gastrointestinal Stromal Tumors
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Gastrointestinal Stromal Tumors
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- clinically-proposed
- derivation note
- Derived from NCI topic(s): Gastrointestinal Stromal Tumors. Strongest NCIt resolution: candidate. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
11 more-specific settings
Gleevec: Gastrointestinal Stromal Tumors with KIT stated without a specific alteration (adjuvant) after prior therapy →Ayvakit: unresectable metastatic Gastrointestinal stromal tumor with PDGFRA stated without a specific alteration →Ayvakit: unresectable metastatic Gastrointestinal stromal tumor with PDGFRA Exon 18, PDGFRA stated without a specific alteration →SUTENT: Gastrointestinal stromal tumor after prior therapy →QINLOCK: advanced Gastrointestinal stromal tumor after prior therapy →Stivarga: unresectable metastatic Gastrointestinal Stromal Tumors →Gastrointestinal Stromal Tumors →Gastrointestinal Stromal Tumors →recurrent Gastrointestinal Stromal Tumors →refractory Gastrointestinal Stromal Tumors →advanced Gastrointestinal Stromal Tumors →
Study evidence for this setting
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Programs To Support You During Chemotherapy
Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
Indication-specific source history
2008-12-19 · Gleevec (imatinib mesylate) · accelerated approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-gastrointestinal-stromal-tumors
- event id
- fda-32f6e9c404cee22a
- event date
- 2008-12-19
- event kind
- accelerated-approval
- drug or regimen
- Gleevec (imatinib mesylate)
- source indication text
- Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)
- match phrase
- gastrointestinal stromal tumors
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4a42bbb412ec8119dff7
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2012-01-31 · Gleevec (imatinib mesylate) · traditional approval
- release id
- clinical-indications-draft-1
- disease state id
- ds-gastrointestinal-stromal-tumors
- event id
- fda-2713a8fbbf981c0e
- event date
- 2012-01-31
- event kind
- traditional-approval
- drug or regimen
- Gleevec (imatinib mesylate)
- source indication text
- Adjuvant treatment of adults following complete gross resection of KIT (CD117) positive gastrointestinal stromal tumors (GIST)
- match phrase
- gastrointestinal stromal tumors
- match status
- candidate
- status category
- verified_clinical_benefit
- has date discrepancy
- 0
- source collection
- fda-status-row
- source key
- fda-aa-4a42bbb412ec8119dff7
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-gastrointestinal-stromal-tumors
- binding id
- ncit-C3868
- source collection
- ncit-concept
- source key
- C3868
- source excerpt
- Source null
- match status
- candidate
- match note
- Resolution status: candidate.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice